Bhaven N Sampat
Affiliation: Columbia University
- Polymorphs and prodrugs and salts (oh my!): an empirical analysis of "secondary" pharmaceutical patentsAmy Kapczynski
Yale Law School, Yale University, New Haven, Connecticut, United States of America
PLoS ONE 7:e49470. 2012..Characterizing the landscape of secondary patents is important in light of recent court decisions in the U.S. that may make them more difficult to obtain, and for developing countries considering restrictions on secondary patents...
- New evidence on the allocation of NIH funds across diseasesBhaven N Sampat
Mailman School of Public Health, Columbia University
Milbank Q 91:163-85. 2013....
- Intellectual property. Challenges to India's pharmaceutical patent lawsBhaven N Sampat
Health Policy and Management, Columbia University, New York, NY 10032, USA
Science 337:414-5. 2012
- Academic patents and access to medicines in developing countriesBhaven N Sampat
Department of Health Policy and Management, the International Center for Health Outcomes and Innovation Research, School of International and Public Affairs, Columbia University, 600 West 168th St, 7th Floor, New York, NY 10032, USA
Am J Public Health 99:9-17. 2009..I provide empirical evidence regarding these issues and explore the feasibility and desirability of proposals to change university patenting and licensing practices to promote access to medicines in the developing world...
- What are the respective roles of the public and private sectors in pharmaceutical innovation?Bhaven N Sampat
Department of Health Policy and Management, School of Public Health, Columbia University, New York City, NY, USA
Health Aff (Millwood) 30:332-9. 2011..Our analyses should help inform thinking about the returns on public research funding-a topic of long-standing interest to economists, policy makers, and health advocates...
- How do public health safeguards in Indian patent law affect pharmaceutical patenting in practice?Bhaven N Sampat
Columbia University, USA
J Health Polit Policy Law 38:735-55. 2013..We find that having the 3(d) provision on the books does not translate into very different patent outcomes in practice in India, relative to Europe, a jurisdiction without this provision. ..